CAJ | 학술논문

目的评价食管癌全程低剂量超分割放射治疗的临床疗效.方法 2000年1月至2001年12月治疗的食管癌患者126例,采用全程超分割放射治疗,120～140 cGy/次,2次/d,5 d/周,放疗总量6400～7400 cGy.结果近期有效率达99.21%,1年生存率61.11%,2年生存率41.27%,5年生存率23.02%;中位生存期1.29年;1年无进展生存(PFS)率57.94%,2年PFS率38.10%,5年PFS率19.84%;中位无进展生存期(TTP)1.16年.结论全程超分割放射治疗食管癌疗效较好,但有待大规模临床试验证实.
목적 평개식관암전정저제량초분할방사치료적림상료효.방법 2000년1월지2001년12월치료적식관암환자126례,채용전정초분할방사치료,120～140 cGy/차,2차/d,5 d/주,방료총량6400～7400 cGy.결과 근기유효솔체99.21%,1년생존솔61.11%,2년생존솔41.27%,5년생존솔23.02%;중위생존기1.29년;1년무진전생존(PFS)솔57.94%,2년PFS솔38.10%,5년PFS솔19.84%;중위무진전생존기(TTP)1.16년.결론 전정초분할방사치료식관암료효교호,단유대대규모림상시험증실.
Objective To evaluate the therapeutic effects of whole course hyperfractionation radiotherapy for esophageal carcinoma. Methods Form January 2000 to December 2001,126 patients with esophageal carcinoma were treated by whole course hyperfractionation radiotherapy(120～140 cGy per fraction, 2 times per day, to a total dose of 6400～7400 cGy) in our department. Results The short-term effective rate was 99.21%. The 1, 2 and 5 year survival rate was 61.11%, 41.27%, 23.02% and the median survival time was 1.29 years. The 1, 2 and 5 year disease-free survival rates was 57.94%, 38.10%, 19.84% and the median disease-free survival time was 1.16 years. Conclusion It is promising of whole course hyperfractionation radiotherapy for esophageal carcinoma. But it must be validated by the large-scale clinical trials.